KZA kazia therapeutics limited

Ann: Kazia releases preliminary Cantrixil Phase I data, page-4

  1. 6,852 Posts.
    lightbulb Created with Sketch. 2536
    "n general, the drug has encountered few dose-limiting toxicities and, as a result, most dosing cohorts have only required enrolment of a single patient, in line with the trial protocol, which has allowed the study to progress with a number of patients towards the lower extent of the forecast range.?

    Great for cost saving but not so good in terms of MTD as we still don't know......but that is a good thing as there seems to be little toxicities at all and SD found in the monotherapy.    Still after a year and half thought we would be sitting on our MTD at least.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.